Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01225315




Registration number
NCT01225315
Ethics application status
Date submitted
19/10/2010
Date registered
21/10/2010
Date last updated
9/07/2018

Titles & IDs
Public title
Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma
Scientific title
A Multi-center, Double-blind, Placebo-controlled, Parallel-group Study to Establish Proof-of-concept and Explore the Efficacy of Different Doses of ACT-129968 in Adult Patients With Partly Controlled Asthma
Secondary ID [1] 0 0
AC-060A202
Universal Trial Number (UTN)
Trial acronym
CONTROL
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Asthma 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Asthma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Setipiprant

Experimental: Setipiprant - Dose 1 - 100 mg b.i.d.

Experimental: Setipiprant - Dose 2 - 500 mg b.i.d.

Experimental: Setipiprant - Dose 3 - 1,000 mg b.i.d

Placebo comparator: Matching Placebo - Oral placebo


Treatment: Drugs: Placebo
Matching placebo administered orally twice daily

Treatment: Drugs: Setipiprant
ACT-129968 (Dose 1, Dose 2, or Dose 3) administered orally twice daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
To demonstrate a change in forced expiratory volume while taking ACT-129968 versus placebo
Timepoint [1] 0 0
Baseline to week 12
Secondary outcome [1] 0 0
Explore the efficacy of different doses of ACT-129968 on change in lung function and asthma control
Timepoint [1] 0 0
Baseline to 12 weeks

Eligibility
Key inclusion criteria
* Signed informed consent prior to any study-mandated procedure
* Males and females age 18 to 65 years
* Women of childbearing potential must use adequate contraception
* Presenting with a diagnosis of asthma according to GINA Guidelines
* Pre-bronchodilator forced expiratory volume in one second (FEV1) < / = 85% of patient's predicted normal value
* Reversibility of airway obstruction of > / = 12% and > / = 200mL from pre-bronchodilator FEV1
* ACQ score > / = 1.5
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* History of life-threatening asthma
* Any asthma exacerbation requiring treatment with systemic corticosteroids within the last 3 months
* Ongoing or recent treatment with medication for allergic airway disease
* Smoking within the last year, or life-time consumption > / = 10 pack-years (e.g., 20 cigarettes/day for 10 years)
* History of chronic pulmonary disease (other than asthma), such as chronic obstructive pulmonary disease (COPD), fibrosis, tuberculosis or sarcoidosis
* Pregnant or lactating women
* Diagnosis of aspirin or non-steroidal anti-inflammatory drug (NSAID)-induced asthma
* Any hospital admission for asthma within the last 6 months
* Anti-IgE therapy at any time check/update interventions by explicitely writing the experimental drug dosage in the interventions description
* Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2012
Sample size
Target
Accrual to date
Final
438
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Clinical Investigative Site 5002 - Glebe
Recruitment hospital [2] 0 0
Clinical Investigative Site 5003 - Nedlands
Recruitment hospital [3] 0 0
Clinical Investigative Site 5001 - Sherwood
Recruitment postcode(s) [1] 0 0
2037 - Glebe
Recruitment postcode(s) [2] 0 0
6009 - Nedlands
Recruitment postcode(s) [3] 0 0
4075 - Sherwood
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Illinois
Country [4] 0 0
United States of America
State/province [4] 0 0
Louisiana
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
Missouri
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Oregon
Country [10] 0 0
United States of America
State/province [10] 0 0
Pennsylvania
Country [11] 0 0
United States of America
State/province [11] 0 0
South Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Tennessee
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
United States of America
State/province [14] 0 0
Wisconsin
Country [15] 0 0
Bulgaria
State/province [15] 0 0
Ruse
Country [16] 0 0
Bulgaria
State/province [16] 0 0
Sofia
Country [17] 0 0
Bulgaria
State/province [17] 0 0
Stara Zagora
Country [18] 0 0
Germany
State/province [18] 0 0
Berlin
Country [19] 0 0
Germany
State/province [19] 0 0
Dortmund
Country [20] 0 0
Germany
State/province [20] 0 0
Gelnhausen
Country [21] 0 0
Germany
State/province [21] 0 0
Hamburg
Country [22] 0 0
Germany
State/province [22] 0 0
Lübeck
Country [23] 0 0
Germany
State/province [23] 0 0
Mainz
Country [24] 0 0
Germany
State/province [24] 0 0
Rüdersdorf
Country [25] 0 0
Hungary
State/province [25] 0 0
Budapest
Country [26] 0 0
Hungary
State/province [26] 0 0
Csorna
Country [27] 0 0
Hungary
State/province [27] 0 0
Miskolc
Country [28] 0 0
Hungary
State/province [28] 0 0
Nyiregyhaza
Country [29] 0 0
Hungary
State/province [29] 0 0
Siofok
Country [30] 0 0
Hungary
State/province [30] 0 0
Sopron
Country [31] 0 0
Hungary
State/province [31] 0 0
Szombathely
Country [32] 0 0
Hungary
State/province [32] 0 0
Sátoraljaújhely
Country [33] 0 0
Hungary
State/province [33] 0 0
Tatabanya
Country [34] 0 0
Israel
State/province [34] 0 0
Ashkelon
Country [35] 0 0
Israel
State/province [35] 0 0
Haifa
Country [36] 0 0
Israel
State/province [36] 0 0
Jerusalem
Country [37] 0 0
Israel
State/province [37] 0 0
Petach Tikvah
Country [38] 0 0
Israel
State/province [38] 0 0
Rehovot
Country [39] 0 0
Israel
State/province [39] 0 0
Tel-Aviv
Country [40] 0 0
Poland
State/province [40] 0 0
Bialystok
Country [41] 0 0
Poland
State/province [41] 0 0
Krakow
Country [42] 0 0
Poland
State/province [42] 0 0
Lodz
Country [43] 0 0
Poland
State/province [43] 0 0
Lublin
Country [44] 0 0
Poland
State/province [44] 0 0
Tarnow
Country [45] 0 0
Russian Federation
State/province [45] 0 0
Barnaul
Country [46] 0 0
Russian Federation
State/province [46] 0 0
Kazan
Country [47] 0 0
Russian Federation
State/province [47] 0 0
Moscow
Country [48] 0 0
Russian Federation
State/province [48] 0 0
Novosibirsk
Country [49] 0 0
Russian Federation
State/province [49] 0 0
St. Petersburg
Country [50] 0 0
Russian Federation
State/province [50] 0 0
Tomsk
Country [51] 0 0
Serbia
State/province [51] 0 0
Belgrade
Country [52] 0 0
Singapore
State/province [52] 0 0
Singapore
Country [53] 0 0
South Africa
State/province [53] 0 0
Bloemfontein
Country [54] 0 0
South Africa
State/province [54] 0 0
Cape Town
Country [55] 0 0
South Africa
State/province [55] 0 0
Durban
Country [56] 0 0
South Africa
State/province [56] 0 0
George
Country [57] 0 0
South Africa
State/province [57] 0 0
Johannesburg
Country [58] 0 0
South Africa
State/province [58] 0 0
Port Elizabeth
Country [59] 0 0
South Africa
State/province [59] 0 0
Pretoria
Country [60] 0 0
Sweden
State/province [60] 0 0
Goteborg
Country [61] 0 0
Sweden
State/province [61] 0 0
Harnosand
Country [62] 0 0
Sweden
State/province [62] 0 0
Linköping
Country [63] 0 0
Sweden
State/province [63] 0 0
Lulea
Country [64] 0 0
Sweden
State/province [64] 0 0
Lund
Country [65] 0 0
Sweden
State/province [65] 0 0
Stockholm
Country [66] 0 0
Sweden
State/province [66] 0 0
Varberg
Country [67] 0 0
Ukraine
State/province [67] 0 0
Donetsk
Country [68] 0 0
Ukraine
State/province [68] 0 0
Kharkiv
Country [69] 0 0
Ukraine
State/province [69] 0 0
Kyiv
Country [70] 0 0
Ukraine
State/province [70] 0 0
Odesa
Country [71] 0 0
Ukraine
State/province [71] 0 0
Poltava
Country [72] 0 0
Ukraine
State/province [72] 0 0
Uzhhorod
Country [73] 0 0
Ukraine
State/province [73] 0 0
Zaporizhia

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Idorsia Pharmaceuticals Ltd.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Sara Mangialaio, MD
Address 0 0
Actelion
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT01225315